دورية أكاديمية
أعرض في EDS

Pretreatment serum albumin/globulin ratio as a prognostic biomarker in metastatic prostate cancer patients treated with maximal androgen blockade.

التفاصيل البيبلوغرافية
العنوان: Pretreatment serum albumin/globulin ratio as a prognostic biomarker in metastatic prostate cancer patients treated with maximal androgen blockade.
المؤلفون: Wang N; Department of Urology, The Third Xiangya Hospital of Central South University, Changsha 410013, China.; Institute of Prostate Disease of Central South University, Changsha 410013, China., Liu JY; Department of Urology, The Third Xiangya Hospital of Central South University, Changsha 410013, China.; Institute of Prostate Disease of Central South University, Changsha 410013, China., Li X; Institute of Prostate Disease of Central South University, Changsha 410013, China.; Center for Molecular Medicine, Xiangya Hospital, Central South University, Changsha 410008, China.; Hunan Key Laboratory of Molecular Radiation Oncology, Xiangya Hospital, Central South University, Changsha 410008, China., Deng MH; Department of Urology, The Third Xiangya Hospital of Central South University, Changsha 410013, China.; Institute of Prostate Disease of Central South University, Changsha 410013, China., Long Z; Department of Urology, The Third Xiangya Hospital of Central South University, Changsha 410013, China.; Institute of Prostate Disease of Central South University, Changsha 410013, China., Tang J; Department of Urology, The Third Xiangya Hospital of Central South University, Changsha 410013, China.; Institute of Prostate Disease of Central South University, Changsha 410013, China., Yao K; Department of Urology, The Third Xiangya Hospital of Central South University, Changsha 410013, China.; Institute of Prostate Disease of Central South University, Changsha 410013, China., Zhang YC; Department of Urology, The Third Xiangya Hospital of Central South University, Changsha 410013, China.; Institute of Prostate Disease of Central South University, Changsha 410013, China., He LY; Department of Urology, The Third Xiangya Hospital of Central South University, Changsha 410013, China.; Institute of Prostate Disease of Central South University, Changsha 410013, China.
المصدر: Asian journal of andrology [Asian J Androl] 2018 Jul 17. Date of Electronic Publication: 2018 Jul 17.
Publication Model: Ahead of Print
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Shanghai Materia Medica Country of Publication: China NLM ID: 100942132 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1745-7262 (Electronic) Linking ISSN: 1008682X NLM ISO Abbreviation: Asian J Androl
أسماء مطبوعة: Publication: Shanghai : Shanghai Materia Medica
Original Publication: Beijing : Science Press,
مستخلص: The pretreatment serum albumin/globulin ratio (AGR) has been used as a prognostic biomarker for various cancer types. However, the prognostic value of the AGR for prostate cancer, especially for metastatic prostate cancer (mPCa) after maximal androgen blockade (MAB), remains unclear. The aim of this study was to evaluate the prognostic value of the pretreatment serum AGR for mPCa treated with MAB. This retrospective study included 214 mPCa patients receiving MAB from October 2007 to March 2017. The correlation of the AGR with survival was estimated using Kaplan-Meier analysis and Cox proportional hazards models. The cutoff value of the AGR was 1.45 according to the receiver operating characteristic curve. Kaplan-Meier analysis demonstrated that patients with a low AGR (<1.45) had poor outcomes in terms of progression-free survival (PFS) and cancer-specific survival (CSS). Multivariate Cox analyses showed that the AGR was an independent predictor of PFS (hazard ratio [HR] = 0.642; 95% confidence interval [CI]: 0.430-0.957; P = 0.030) and CSS (HR = 0.412; 95% CI: 0.259-0.654; P < 0.001). Furthermore, in a subset of 79 patients with normal serum albumin levels (≥40.0 g l -1 ), the serum AGR remained an independent predictor of CSS (P = 0.009). The pretreatment AGR was an independent prognostic biomarker for PFS and CSS in patients with mPCa receiving MAB. In addition, the AGR remained effective for the prediction of CSS in patients with normal albumin levels (≥40 g l -1 ). However, further prospective studies are needed to confirm our conclusions.
References: Nutr Cancer. 1999;35(2):106-10. (PMID: 10693162)
Lancet. 2001 Feb 17;357(9255):539-45. (PMID: 11229684)
Nutr Cancer. 2001;39(2):210-3. (PMID: 11759282)
Eur Urol. 2002 Apr;41(4):363-71. (PMID: 12074805)
Nature. 2002 Dec 19-26;420(6917):860-7. (PMID: 12490959)
BJU Int. 2004 Jun;93(9):1177-82. (PMID: 15180600)
Int J Cancer. 2006 Nov 15;119(10):2402-7. (PMID: 16894564)
Clin Chem Lab Med. 2007;45(3):419-26. (PMID: 17378745)
Anticancer Res. 2007 Jul-Aug;27(4C):3001-4. (PMID: 17695486)
Urol Int. 2008;80(2):129-33. (PMID: 18362480)
Curr Opin Clin Nutr Metab Care. 2008 May;11(3):248-54. (PMID: 18403920)
Am J Clin Nutr. 2008 Jun;87(6):1678-85. (PMID: 18541556)
Future Oncol. 2008 Oct;4(5):637-45. (PMID: 18922121)
Mol Nutr Food Res. 2009 Feb;53(2):171-84. (PMID: 19101947)
BJU Int. 2009 Jul;104(1):20-4. (PMID: 19239456)
Carcinogenesis. 2009 Jul;30(7):1073-81. (PMID: 19468060)
Cancer. 2009 Aug 1;115(15):3376-8. (PMID: 19484788)
Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):35-41. (PMID: 20092961)
Cell. 2010 Mar 19;140(6):883-99. (PMID: 20303878)
Cancer Sci. 2010 Dec;101(12):2652-7. (PMID: 20942896)
Nutr J. 2010 Dec 22;9:69. (PMID: 21176210)
Am J Epidemiol. 2011 Apr 1;173(7):721-30. (PMID: 21367875)
J Epidemiol. 2011;21(3):161-8. (PMID: 21368452)
Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
Prostate. 2011 Jun 1;71(8):899-907. (PMID: 21456072)
Med Oncol. 2012 Sep;29(3):2005-9. (PMID: 21735143)
J Clin Invest. 1990 Jan;85(1):248-55. (PMID: 2295699)
Urology. 2012 Dec;80(6):1328-32. (PMID: 23063057)
Asian J Androl. 2013 Jan;15(1):110-5. (PMID: 23147466)
Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):317-23. (PMID: 23474109)
BMC Cancer. 2013 Jun 17;13:292. (PMID: 23768149)
Int J Colorectal Dis. 2013 Dec;28(12):1629-36. (PMID: 23857599)
Am J Surg. 2013 Nov;206(5):764-70. (PMID: 23866764)
Prostate Int. 2013;1(2):47-58. (PMID: 24223402)
Eur Urol. 2014 Feb;65(2):467-79. (PMID: 24321502)
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29. (PMID: 24399786)
Nat Rev Urol. 2014 Apr;11(4):197-212. (PMID: 24595118)
PLoS One. 2014 Apr 09;9(4):e94473. (PMID: 24718309)
J Immunother. 2014 Sep;37(7):366-73. (PMID: 25075566)
J Thorac Dis. 2014 Sep;6(9):1261-70. (PMID: 25276368)
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. (PMID: 26808342)
Medicine (Baltimore). 2016 Mar;95(12):e3097. (PMID: 27015181)
Rev Esp Enferm Apar Dig. 1989 Feb;75(2):143-8. (PMID: 2710997)
Urol Oncol. 2016 Nov;34(11):484.e1-484.e8. (PMID: 27341738)
Biomed Res Int. 2017;2017:3083267. (PMID: 28424782)
Cancer Treat Rep. 1981 Mar-Apr;65(3-4):187-95. (PMID: 6263468)
J Allergy Clin Immunol. 1997 Aug;100(2):151-7. (PMID: 9275133)
Arch Surg. 1999 Jan;134(1):36-42. (PMID: 9927128)
فهرسة مساهمة: Keywords: albumin/globulin ratio; maximal androgen blockade; metastatic prostate cancer; prognosis; survival
تواريخ الأحداث: Date Created: 20180721 Latest Revision: 20240227
رمز التحديث: 20240227
مُعرف محوري في PubMed: PMC6337948
DOI: 10.4103/aja.aja_50_18
PMID: 30027930
قاعدة البيانات: MEDLINE
الوصف
تدمد:1745-7262
DOI:10.4103/aja.aja_50_18